Neuroscientist Hoau-Yan Wang, known for his work on an Alzheimer’s drug candidate, has been indicted on charges of fraud. Allegations include the fabrication of research images and data to secure grants, casting doubt on his contributions to the field. Wang collaborated with Cassava Sciences on simufilam, a drug in late-stage clinical trials, receiving millions in grants. The indictment accuses Wang of fraud, wire fraud, and false statements, citing manipulation of research images and deception of scientific journals. Despite Wang's denial of data manipulation, multiple retractions of his studies have raised concerns. The case highlights growing concerns about research image manipulation and scientific integrity. Wang's indictment, along with recent investigations into other scientists, underscores the importance of maintaining research ethics and transparency in academic and pharmaceutical collaborations.